Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative bioavailability crossover study of hydromethylthionine mesylate tablet formulations in healthy adults
NL-OMON60421Phase 1Completed
- Sponsor
- TauRx Therapeutics Ltd
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of hydromethylthionine mesylate in Alzheimer's disease (AD) (6 arms), sponsored by TauRx Therapeutics Ltd. Primary endpoint: Primary endpoint not publicly disclosed. Started Mar 2024; status: completed.
02
Drugs
hydromethylthionine mesylate
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON60421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60421.